Page 1 | Search Results | Blood | American Society of Hematology

1-12 of 12

Sort by

Sort Order Select

Journal Articles

Phase 1b Study of Carfilzomib in Combination with Induction Chemotherapy in Children with Relapsed or Refractory Acute Lymphoblastic Leukemia (ALL)

Michael J. Burke, MD, David S. Ziegler, MBBS, FRACP, MD, Francisco José Bautista Sirvent, MD PhD, Andishe Attarbaschi, MD, Lia Gore, MD, Franco Locatelli, MD PhD, Maureen M O'Brien, MD, Melinda Pauly, MD, Mihaela Obreja, PhD, Christopher L. Morris, PhDMD, Andre Baruchel, MD

Blood (2019) 134 (Supplement_1): 3873.

https://doi.org/10.1182/blood-2019-127350

Published: 2019

Journal Articles

A Drug-Regulated CAR Platform (DARIC) Induces Effective and Reversible Tumor Control In Vivo Using Non-Immunosuppressive Rapamycin Dosing

Wai-Hang Leung, PhD, Michael T Certo, PhD, Holly M. Horton, PhD, Joel Gay, Tracy VandenBerg, Jordan Jarjour, PhD, Alexander Astrakhan, PhD

Blood (2017) 130 (Supplement 1): 1910.

https://doi.org/10.1182/blood.V130.Suppl_1.1910.1910

Published: 2017

Journal Articles

ROR1-Directed Chimeric Antigen Receptor T Cell Recognition of Self-Antigen Is Associated with Acute Toxicity, T Cell Dysfunction, and Poor Tumor Control.

James B Rottman, DVM, PhD DACVP, Kenneth Ganley, BS, Brenna Daly, BS, Holly M. Horton, PhD, Kevin M. Friedman, Molly Perkins, PhD, Shannon Grande, PhD, Claire J Rhodes, BS, Richard A. Morgan, PhD, Christopher J. Horvath, DVM, MS, DACVP

Blood (2017) 130 (Supplement 1): 4450.

https://doi.org/10.1182/blood.V130.Suppl_1.4450.4450

Published: 2017

Journal Articles

Who Is Receiving Novel Therapies for Relapsed/Refractory Follicular Lymphoma? a Retrospective Chart Review of Recent Real-World Practice

James Signorovitch, PhD, Viviana Garcia-Horton, PhD, Marie Louise Ricculli, MS, Michael McGuire, PharmD

Blood (2017) 130 (Supplement 1): 4707.

https://doi.org/10.1182/blood.V130.Suppl_1.4707.4707

Published: 2017

Journal Articles

Brief Research Report: Novel Compound BCR-ABL Mutations in Late Chronic Phase Imatinib Sensitive CML Patients Are Associated with Progression to Advance Disease Phase

Zafar Iqbal, MPhil PhDPost-doc., Afia Muhammad Akram, Tanveer Akhtar, PhD, Aamer Aleem, MBBS FRCP, Muhammad Farooq Sabar, PhD, Zeba Aziz, MD MBBS, Nadia Sajid, Mahmood Rasool, PhD, Muhammad Asif, Mehmood Husssain Qazi, PhD, Saleh Oraibi, PhD, Ammara T Gill, MBBS ABIM, Khalid Al Jamaan, MDFRCPC, Mudassar Iqbal, MDMS, Ahmad Mukhtar Khalid

Blood (2016) 128 (22): 3089.

https://doi.org/10.1182/blood.V128.22.3089.3089

Published: 2016

Journal Articles

Manufacturing an Enhanced CAR T Cell Product By Inhibition of the PI3K/Akt Pathway During T Cell Expansion Results in Improved In Vivo Efficacy of Anti-BCMA CAR T Cells

Molly R. Perkins, D.Phil., Shannon Grande, PhD, Amanda Hamel, BS, Holly M. Horton, PhD, Tracy E. Garrett, BA, Sara M. Miller, Howard J. Latimer, IV, BS, Christopher J. Horvath, DVM, MS, DACVP, Michael Kuczewski, MS, Kevin M. Friedman, PhD, Richard A. Morgan, PhD

Blood (2015) 126 (23): 1893.

https://doi.org/10.1182/blood.V126.23.1893.1893

Published: 2015

Journal Articles

A Novel and Highly Potent CAR T Cell Drug Product for Treatment of BCMA-Expressing Hematological Malignances

Alena A. Chekmasova, PhD, Holly M. Horton, PhD, Tracy E. Garrett, BA, John W. Evans, PhD, Johanna Griecci, BS, Amanda Hamel, BS, Howard J. Latimer, IV, BS, Stacie L. Seidel, MA, Byoung Y. Ryu, PhD, Michael Kuczewski, MS, Christopher J. Horvath, DVM, MS, DACVP, Kevin M. Friedman, PhD, Richard A. Morgan, PhD

Blood (2015) 126 (23): 3094.

https://doi.org/10.1182/blood.V126.23.3094.3094

Published: 2015

Journal Articles

Results of a Feasibility and Phase II Study on Bortezomib (BTZ) in Pediatric Multiply Relapsed or Refractory Acute Lymphoblastic Leukemia: Complete Hematological Responses with a Modestly Intensive Regimen Including BTZ

Gertjan Kaspers, MD PhD, Denise Niewerth, MSc, Satianand Ramnarain, MSc, Andishe Attarbaschi, MD, André Baruchel, MD, Evelina S De Bont, MDPhD, Franca Fagioli, MD, Barbara De Moerloose, MD PhD, Karsten Nysom, MD, Giuseppe Palumbo, MD, Dirk Reinhardt, MD PhD, Pierre-Simon Rohrlich, MDPhD, Pauline Simon, MD, Arend von Stackelberg, MD, C. Michel Zwaan, MD PhD

Blood (2014) 124 (21): 2290.

https://doi.org/10.1182/blood.V124.21.2290.2290

Published: 2014

Journal Articles

Pharmacokinetic Results Of a Feasibility and Phase II Study (ITCC 021) On Bortezomib (BTZ) In Pediatric Relapsed ALL: Lack Of Significant Penetration Of BTZ In The Cerebrospinal Fluid

Gertjan Kaspers, MD, PhD, Ron Mathot, PharmD PhD, Satianand Ramnarain, MSc, Denise Niewerth, MSc, Franco Locatelli, MD, PhD, Eveline S.J.M De Bont, MD, PhD, Franca Fagioli, MD, Pierre Rohrlich, MD, Arend von Stackelberg, Michel Zwaan

Blood (2013) 122 (21): 1439.

https://doi.org/10.1182/blood.V122.21.1439.1439

Published: 2013

Journal Articles

Hypercvad+Bortezomib Is a Well Tolerated Salvage Regimen for Relapsed/Refractory Adult Acute Lymphoblastic Leukemia

Jyotishankar Raychaudhuri, MBBS, Mudhasir Ahmad, MD, Manas Kalra, Harsh Dua, MD, Rakesh Chopra, MD, Sangeeta Rawat, Rashmi Thakur

Blood (2010) 116 (21): 4345.

https://doi.org/10.1182/blood.V116.21.4345.4345

Published: 2010

Journal Articles

XmAb®5592 Fc-Engineered Humanized Anti-HM1.24 Monoclonal Antibody Has Potent in Vitro and In Vivo Efficacy against Multiple Myeloma.

Yu-Tzu Tai, Ph.D., Umesh Muchhal, Ph.D., Xian-Feng Li, MS, Sabikun Nahar, B.S., Weihua Song, MD, Holly Horton, Ph.D, Hanh Nguyen, Sher Karki, John Desjarlais, Nikhil C. Munshi, MD, Paul Richardson, M.D., Ph.D., Kenneth C. Anderson, MD

Blood (2009) 114 (22): 609.

https://doi.org/10.1182/blood.V114.22.609.609

Published: 2009

Journal Articles

Allogeneic Hematopoietic Stem Cell Transplantation for Myeloma: Does the Melphalan Dose Matter?.

Jayesh Mehta, Sandeep Chunduri, Lisa Dobogai, Seema Singhal, Damiano Rondelli

Blood (2007) 110 (11): 3035.

https://doi.org/10.1182/blood.V110.11.3035.3035

Published: 2007

NARROW

Phase 1b Study of Carfilzomib in Combination with Induction Chemotherapy in Children with Relapsed or Refractory Acute Lymphoblastic Leukemia (ALL)

A Drug-Regulated CAR Platform (DARIC) Induces Effective and Reversible Tumor Control In Vivo Using Non-Immunosuppressive Rapamycin Dosing

ROR1-Directed Chimeric Antigen Receptor T Cell Recognition of Self-Antigen Is Associated with Acute Toxicity, T Cell Dysfunction, and Poor Tumor Control.

Who Is Receiving Novel Therapies for Relapsed/Refractory Follicular Lymphoma? a Retrospective Chart Review of Recent Real-World Practice

Brief Research Report: Novel Compound BCR-ABL Mutations in Late Chronic Phase Imatinib Sensitive CML Patients Are Associated with Progression to Advance Disease Phase

Manufacturing an Enhanced CAR T Cell Product By Inhibition of the PI3K/Akt Pathway During T Cell Expansion Results in Improved In Vivo Efficacy of Anti-BCMA CAR T Cells

A Novel and Highly Potent CAR T Cell Drug Product for Treatment of BCMA-Expressing Hematological Malignances

Results of a Feasibility and Phase II Study on Bortezomib (BTZ) in Pediatric Multiply Relapsed or Refractory Acute Lymphoblastic Leukemia: Complete Hematological Responses with a Modestly Intensive Regimen Including BTZ

Pharmacokinetic Results Of a Feasibility and Phase II Study (ITCC 021) On Bortezomib (BTZ) In Pediatric Relapsed ALL: Lack Of Significant Penetration Of BTZ In The Cerebrospinal Fluid

Hypercvad+Bortezomib Is a Well Tolerated Salvage Regimen for Relapsed/Refractory Adult Acute Lymphoblastic Leukemia

XmAb®5592 Fc-Engineered Humanized Anti-HM1.24 Monoclonal Antibody Has Potent in Vitro and In Vivo Efficacy against Multiple Myeloma.

Allogeneic Hematopoietic Stem Cell Transplantation for Myeloma: Does the Melphalan Dose Matter?.

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only